These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 21286912)

  • 1. Three years of paediatric regulation in the European Union.
    Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
    Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
    Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
    Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paediatric investigation plans for pain: painfully slow!
    Davies EH; Ollivier CM; Saint Raymond A
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1091-7. PubMed ID: 20821198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral medicines for children in the European paediatric investigation plans.
    van Riet-Nales DA; Römkens EG; Saint-Raymond A; Kozarewicz P; Schobben AF; Egberts TC; Rademaker CM
    PLoS One; 2014; 9(6):e98348. PubMed ID: 24897509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
    Carleer J; Karres J
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Who are the PDCO?
    Dempsey EM; Connolly K
    Eur J Pediatr; 2014 Feb; 173(2):233-5. PubMed ID: 23925423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The European Regulation on medicines for paediatric use.
    Dunne J
    Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EU paediatric regulation: still a large discrepancy between therapeutic needs and approved paediatric investigation plans.
    Wimmer S; Rascher W; McCarthy S; Neubert A
    Paediatr Drugs; 2014 Oct; 16(5):397-406. PubMed ID: 25056717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
    Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
    Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
    Hwang TJ; Tomasi PA; Bourgeois FT
    PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA from 2007-2013.
    Egger GF; Wharton GT; Malli S; Temeck J; Murphy MD; Tomasi P
    Ther Innov Regul Sci; 2016 Sep; 50(5):639-647. PubMed ID: 27274951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Paediatric Medicines Development: Have Paediatric Investigation Plans Lost Heart?
    Faulkner B; Delgado-Charro MB
    Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33276598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia.
    Rose K; Walson PD
    Risk Manag Healthc Policy; 2015; 8():185-205. PubMed ID: 26604845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.
    Stefanska AM; Distlerová D; Musaus J; Olski TM; Dunder K; Salmonson T; Mentzer D; Müller-Berghaus J; Hemmings R; Veselý R
    Arch Dis Child; 2017 Oct; 102(10):952-957. PubMed ID: 28554892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
    Rose K; Senn S
    Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare?
    Rose K; Walson PD
    Paediatr Drugs; 2017 Dec; 19(6):515-522. PubMed ID: 28889403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.